Junya Zhu1,2, G Caleb Alexander3,4, Saman Nazarian4,5, Jodi B Segal1,3,4, Albert W Wu1,4. 1. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 2. OptumLabs, Cambridge, Massachusetts. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 4. Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland. 5. The University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Abstract
OBJECTIVE: Since 2010, several non-vitamin K antagonist oral anticoagulants (NOACs) have been brought to the U.S. market, yet little is known regarding their evolving adoption for prophylaxis of atrial fibrillation (AF)-related stroke. We examined temporal trends in choice of oral anticoagulants (OACs) among incident OAC users with AF and its association with patient demographic and clinical characteristics. METHODS: We conducted a serial cross-sectional analysis of medical and pharmacy claims for commercial and Medicare Advantage enrollees in a large, private, U.S. health plan. We identified 112,187 adults with nonvalvular AF starting OACs between October 2010 and March 2017. Multivariable logistic regression was used to examine the associations of patient characteristics with prescription of NOACs versus warfarin. Multinomial logistic regression was used to test the associations of patient characteristics with choice among NOACs. RESULTS: The prescription of NOACs has increased dramatically since their introduction in October 2010. In the first quarter of 2017 (2017Q1), 7502 patients started OACs, of whom 78.9% used NOACs and 21.1% warfarin. For NOACs, 3.8% used dabigatran, 25.0% rivaroxaban, and 50.1% apixaban. In multivariable analyses, factors associated with choice of NOACs versus warfarin included younger age, lower stroke or bleeding risk, fewer comorbidities, higher education level or household net worth, and prescription by cardiologists (all p<0.001). There was no sex difference in likelihood of filling NOACs versus warfarin in 2010Q4-2012, but women had higher odds of starting NOACs (odds ratio = 1.19; 95% confidence interval = 1.14-1.25) in 2015-2017Q1. Among NOAC users, the odds of apixaban prescription increased with age, female sex, stroke or bleeding risk, and comorbidities (all p<0.05). CONCLUSION: NOAC prescriptions have increased substantially among incident OAC users with nonvalvular AF, predominantly driven by increased prescription of apixaban. Warfarin and apixaban were generally preferred for elderly patients, patients with higher stroke or bleeding risk, and patients with more comorbidities.
OBJECTIVE: Since 2010, several non-vitamin K antagonist oral anticoagulants (NOACs) have been brought to the U.S. market, yet little is known regarding their evolving adoption for prophylaxis of atrial fibrillation (AF)-related stroke. We examined temporal trends in choice of oral anticoagulants (OACs) among incident OAC users with AF and its association with patient demographic and clinical characteristics. METHODS: We conducted a serial cross-sectional analysis of medical and pharmacy claims for commercial and Medicare Advantage enrollees in a large, private, U.S. health plan. We identified 112,187 adults with nonvalvular AF starting OACs between October 2010 and March 2017. Multivariable logistic regression was used to examine the associations of patient characteristics with prescription of NOACs versus warfarin. Multinomial logistic regression was used to test the associations of patient characteristics with choice among NOACs. RESULTS: The prescription of NOACs has increased dramatically since their introduction in October 2010. In the first quarter of 2017 (2017Q1), 7502 patients started OACs, of whom 78.9% used NOACs and 21.1% warfarin. For NOACs, 3.8% used dabigatran, 25.0% rivaroxaban, and 50.1% apixaban. In multivariable analyses, factors associated with choice of NOACs versus warfarin included younger age, lower stroke or bleeding risk, fewer comorbidities, higher education level or household net worth, and prescription by cardiologists (all p<0.001). There was no sex difference in likelihood of filling NOACs versus warfarin in 2010Q4-2012, but women had higher odds of starting NOACs (odds ratio = 1.19; 95% confidence interval = 1.14-1.25) in 2015-2017Q1. Among NOAC users, the odds of apixaban prescription increased with age, female sex, stroke or bleeding risk, and comorbidities (all p<0.05). CONCLUSION: NOAC prescriptions have increased substantially among incident OAC users with nonvalvular AF, predominantly driven by increased prescription of apixaban. Warfarin and apixaban were generally preferred for elderly patients, patients with higher stroke or bleeding risk, and patients with more comorbidities.
Authors: Nils Schoof; Janet Schnee; Gary Schneider; Melissa Gawlik; Kristina Zint; Andreas Clemens; Dorothee B Bartels Journal: Curr Med Res Opin Date: 2014-01-16 Impact factor: 2.580
Authors: J B Olesen; G Y H Lip; P R Hansen; J Lindhardsen; O Ahlehoff; C Andersson; P Weeke; M L Hansen; G H Gislason; C Torp-Pedersen Journal: J Thromb Haemost Date: 2011-08 Impact factor: 5.824
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: Gregory Y H Lip; Stephen A Mitchell; Xianchen Liu; Larry Z Liu; Hemant Phatak; Sumesh Kachroo; Sarah Batson Journal: Int J Cardiol Date: 2015-11-17 Impact factor: 4.164
Authors: Elaine M Hylek; Alan S Go; Yuchiao Chang; Nancy G Jensvold; Lori E Henault; Joe V Selby; Daniel E Singer Journal: N Engl J Med Date: 2003-09-11 Impact factor: 91.245
Authors: Lauren E Thompson; Thomas M Maddox; Lanyu Lei; Gary K Grunwald; Steven M Bradley; Pamela N Peterson; Frederick A Masoudi; Alexander Turchin; Yang Song; Gheorghe Doros; Melinda B Davis; Stacie L Daugherty Journal: J Am Heart Assoc Date: 2017-07-19 Impact factor: 5.501
Authors: Emily K Acton; Michael A Gelfand; Sean Hennessy; Sharon X Xie; John R Pollard; Scott E Kasner; Allison W Willis Journal: Epilepsy Behav Date: 2020-11-24 Impact factor: 2.937
Authors: Weijia Wang; Jane Saczynski; Darleen Lessard; Tanya Mailhot; Bruce Barton; Molly E Waring; Felix Sogade; Robert Hayward; Robert Helm; David D McManus Journal: J Cardiovasc Electrophysiol Date: 2019-09-25
Authors: Christopher W Baugh; Michael Levine; David Cornutt; Jason W Wilson; Richard Kwun; Charles E Mahan; Charles V Pollack; Evie G Marcolini; Truman J Milling; W Frank Peacock; Rachel P Rosovsky; Fred Wu; Ravi Sarode; Alex C Spyropoulos; Todd C Villines; Timothy D Woods; John McManus; James Williams Journal: Ann Emerg Med Date: 2019-11-13 Impact factor: 5.721
Authors: Matthew Alcusky; Jennifer Tjia; David D McManus; Anne L Hume; Marc Fisher; Kate L Lapane Journal: J Gen Intern Med Date: 2020-04-06 Impact factor: 5.128
Authors: Andrea L Porter; Amanda R Margolis; Carla E Staresinic; Michael W Nagy; Rebecca R Schoen; Cheryl A Ray; Christopher D Fletcher Journal: J Thromb Thrombolysis Date: 2019-02 Impact factor: 2.300
Authors: Marie Bradley; Emily C Welch; Efe Eworuke; David J Graham; Rongmei Zhang; Ting-Ying Huang Journal: J Gen Intern Med Date: 2020-09-28 Impact factor: 5.128